SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-018299
Filing Date
2022-05-05
Accepted
2022-05-05 16:42:39
Documents
65
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q eigr-10q_20220331.htm   iXBRL 10-Q 2272692
2 EX-31.1 eigr-ex311_8.htm EX-31.1 16839
3 EX-31.2 eigr-ex312_7.htm EX-31.2 16903
4 EX-32.1 eigr-ex321_9.htm EX-32.1 5739
  Complete submission text file 0001564590-22-018299.txt   8279315

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA eigr-20220331.xsd EX-101.SCH 55360
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE eigr-20220331_cal.xml EX-101.CAL 57098
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE eigr-20220331_def.xml EX-101.DEF 147899
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20220331_lab.xml EX-101.LAB 420662
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20220331_pre.xml EX-101.PRE 313641
59 EXTRACTED XBRL INSTANCE DOCUMENT eigr-10q_20220331_htm.xml XML 1568013
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36183 | Film No.: 22897155
SIC: 2836 Biological Products, (No Diagnostic Substances)